A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Hyperlipidemia

Interventions

DRUG

A: NK-104-CR 8 mg

NK-104-CR 8 mg (Controlled Release single 8-mg tablet)

DRUG

B: Pitavastatin IR 4 mg

Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)

DRUG

C: Pitavastatin IR 8 mg

Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)

Trial Locations (1)

Austin